

Group II - Claims 6-19 and 21, drawn to a transformant and corresponding therapeutic agent.

Group III - Claims 22-23, drawn to a method for screening an agonist or antagonist.

In response, Applicants elect **Group I, claims 1-4 and 20**, without traverse.

The Examiner further states that the application contains claims directed to more than one species of the generic invention. The Examiner states that if Applicants elect Group I, Applicants must further elect as between the following species of Fas antigen:

A) human


B) mouse

In response, Applicants elect **B) the mouse Fas antigen** as the species, without traverse.

In view of the above, reconsideration and allowance of this application are now believed to be in order, and such action is hereby solicited. If any points remain in issue which the Examiner feels may be best resolved through a personal or telephone interview, he is kindly requested to contact the undersigned at the telephone number listed below.

Applicants hereby petition for any extension of time which may be required to maintain the pendency of this case, and any required fee, except for the Issue Fee, for such extension is to be charged to Deposit Account No. 19-4880.

Respectfully submitted,



Drew Hissong
Registration No. 44,765

SUGHRUE MION, PLLC
2100 Pennsylvania Avenue, N.W.
Washington, D.C. 20037-3213
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

Date: November 21, 2001